Risk of post-transplant malignancy: a single center retrospective comparative study between everolimus and mycophenolate in kidney transplant recipients.

Authors

Lucia Federica Stefanelli, Martina Cacciapuoti, Marianna Alessi, Cristina Silvestre, Francesca Katiana Martino, Dorella Del Prete, Lorenzo A Calò, Federico Nalesso

Published in

Journal of nephrology. Aug 03, 2026. Epub Aug 03, 2026.

Abstract

While cardiovascular and infection-related mortality have improved with transplant care, malignancy-related deaths have shown no significant change. Post-transplant malignancy risk is attributed to immunosuppression but the effect on graft outcome and cancer development is not clearly determined.
A monocentric-retrospective study on 159 single or double kidney transplant recipients (KTRs) followed at the Padova University Hospital, Kidney-Pancreas Transplant Ambulatory Unit, who underwent kidney transplantation between January 2015 and December 2018, was performed to investigate the immunosuppression role in cancer development via comparison between patients treated with mTORi (everolimus) and with mycophenolate (mean observation 7 years). Cancer trend, cancer type, mortality and graft survival rate in KTRs receiving different immunosuppression protocols were also investigated.
54 patients had de novo cancers, most common skin cancer (non-melanoma) ; no significant association was found between the 2 groups of KTRs as for de novo malignancies development. Multivariable logistic regression indicated age, HCV and history of pretransplant malignancy predictors of cancer development. Patients and graft survival during the follow-up were higher in mycophenolate group, while the rejection rate was lower although not significant in the everolimus group. mTORi was not associated with de novo significant cancer reduction vs mycophenolate. Older age, HCV and history of pretransplant cancer were associated with cancer development.
Our study suggests that older KTRs are more likely to develop post-transplant malignancies indicating that individualized minimization of immunosuppression may be considered in selected older KTRs after careful assessment of the balance between malignancy risk and graft outcomes.

PMID:
42544510
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.